Pockros Paul J
Dr. Pockros serves as Head of the Division of Gastroenterology and Hepatology and Director of the SC Liver Research Consortium at the Scripps Clinic in La Jolla, California. He is also a Skaggs Scholar at The Scripps Research Institute in La Jolla, California.
Gastroenterol Hepatol (N Y). 2008 Oct;4(10):729-34.
Current hepatitis C virus (HCV) therapies are associated with significant adverse events and less-than-ideal sustained virologic response (SVR) rates in genotype 1 patients. The current standard of care, a combination of pegylated interferon and ribavirin, will likely remain a key component of the treatment regimen for years to come. Multiple new drugs are currently in development and are expected to be approved for use in the United States and/or European Union by 2011 at the earliest. Future therapies will include novel interferons, ribavirin analogues, NS3 HCV protease inhibitors, NS5b HCV polymerase inhibitors, cyclophilin inhibitors, and other novel agents. There is hope that multiple new drugs will be approved over the following 4-10 years to provide alternative treatment choices, improved SVR rates, and reductions in adverse events. However, a number of barriers must be overcome prior to the acceptance of these drugs, involving, but not limited to, their toxicity, viral resistance, optimal dose, duration, and their efficacy and safety in patients with unmet needs.
目前的丙型肝炎病毒（HCV）疗法与显著的不良事件相关，并且在1型基因型患者中持续病毒学应答（SVR）率不尽人意。当前的标准治疗方案，即聚乙二醇化干扰素和利巴韦林联合使用，在未来数年可能仍将是治疗方案的关键组成部分。目前有多种新药正在研发中，最早预计在2011年获美国和/或欧盟批准使用。未来的治疗方法将包括新型干扰素、利巴韦林类似物、NS3 HCV蛋白酶抑制剂、NS5b HCV聚合酶抑制剂、亲环蛋白抑制剂以及其他新型药物。人们希望在接下来的4至10年里能有多种新药获批，以提供更多的治疗选择、提高SVR率并减少不良事件。然而，在这些药物被接受之前必须克服一些障碍，包括但不限于它们的毒性、病毒耐药性、最佳剂量、疗程以及它们在有未满足需求患者中的疗效和安全性。
